Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4282 | Waiting list where participants wait for delayed treatment Wiki | 1.00 |
| drug514 | Baricitinib Wiki | 0.38 |
| drug3319 | Remdesivir Wiki | 0.19 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Few older adults receive treatment for Generalized Anxiety Disorder (GAD) despite a high prevalence in this population and significant associated health care costs. Although older adults generally prefer psychotherapy to medication for help with anxiety, face-to-face psychotherapy is difficult to access for many of them. Psychological guided self-help (GSH), which patients use by themselves at home under the supervision of a licensed mental health provider (e.g., psychologist), has been shown to be effective. However, the capacity of our health care system to respond adequately to the mental health needs of seniors has been questioned and cost-effective solutions are required. Because the therapist's role in GSH is limited to supporting the patient, it is conceivable that this role could be assumed by trained and supervised lay providers (LP) instead of licensed providers. If this approach is effective, it could help provide many older adults with much needed mental health treatment at a lower cost. The main objective of this project is to evaluate the effectiveness of GSH guided by LP for GAD in older adults. Participants will be assigned randomly to an experimental group, which will receive treatment immediately, or to a control group whose treatment will be delayed. Data will be obtained through clinician evaluations and self-assessment questionnaires. They will include socio-demographic characteristics, symptoms of GAD, variables related to anxiety, such as depression and sleep difficulties, and participants' perception of treatment. For the experimental group, data collection will take place at four different times: before treatment begins, after treatment ends, and at 6 and 12 months after the end of treatment. Control group participants will be assessed on three occasions: before and after the waiting period and after receiving treatment. The efficacy of GSH will be established by comparing the change in the two groups on the main variables. We will also identify the characteristics of patients associated with improvement during treatment and document their perception of treatment.
Description: 16 items rated on a scale ranging from 1 to 5. A higher total score indicates a greater tendency to worry.
Measure: Change in Penn State Worry Questionnaire Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 7 items answered on a scale ranging from 0 to 3. A higher total score suggests greater severity.
Measure: Change in GAD-7 Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 27 items rated on a scale ranging from 1 to 5. A higher total score suggests higher intolerance to uncertainty.
Measure: Change in Intolerance to Uncertainty Inventory Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 12 items rated on a scale ranging from 1 to 5. A higher total score suggests more negative attitudes toward problems.
Measure: Change in Negative Problem Orientation Questionnaire Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 25 items rated on a scale ranging from 1 to 5. A higher total score suggests more likely use of cognitive avoidance.
Measure: Change in Cognitive Avoidance Questionnaire Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 25 items rated on a scale ranging from 1 to 5. A higher total score suggests a greater belief that worrying is useful.
Measure: Change in Why Worry Questionnaire Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 20 items rated as "agree" or "disagree". Minimum score = 0; Maximum score = 20. A higher total score is indicative of greater severity of symptoms.
Measure: Change in Geriatric Anxiety Inventory Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 30 items rated as "yes" or "no". Minimum score = 0; Maximum score = 30.A higher total score is indicative of greater severity of symptoms.
Measure: Change in Geriatric Depression Scale Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: 7 items rated on a scale ranging from 1 to 4. A higher total score suggests more severe insomnia.
Measure: Change in Insomnia Severity Index Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: Three self-rated items of family, work, and social impairment rated on a scale ranging from 0 to 10.
Measure: Change in Sheehan Disability Scale Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: Measures knowledge about anxiety. 22 items answered with one of three options - true, false or don't know. Minimum score = 0; maximum score = 22. Higher scores indicate higher mental health literacy of anxiety.
Measure: Change in Anxiety Literacy Questionnaire. Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: Each of the 6 items describes a specific situation for which individuals providing support are listed and perceived support is rated on a 6-point likert scale from "very dissatisfied" to "very satisfied".
Measure: Change in Short version of Sarason's Social Support Questionnaire Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: Measures participant's perception of treatment. 19 statements covering various aspects of treatment (modules, readings, exercises, telephone sessions, workload, organization and duration of treatment, and its usefulness). Each statement is evaluated on a four-point scale ranging from "strongly agree" to "absolutely disagree". A fifth possible answer, 'does not apply', is also provided.
Measure: Evaluation of treatment by participants Time: Post treatment (15 weeks)Description: Measures the dimensions of an individual's motivation for entering treatment. Twenty items are listed on a 7-point Likert scale ranging from 1 (not at all true) to 7 (very true).
Measure: Treatment Motivation Questionnaire Time: Baseline and post treatment.Description: Evaluates how each participant views the credibility of the treatment and the possible improvements that can be achieved from the treatment. The 6 items are listed on a 9-point Likert scale, with a higher score indicating more trust in the treatment.
Measure: Credibility/Expectancy Questionnaire Time: Baseline and post treatment.Description: Twelve items that assess the quality of the relationship between the participant and his LP. The WAI has two versions: one for the participant and another for the LP. The items are listed on a 7-point Likert scale, with higher scores indicative of greater alliance.
Measure: Working Alliance Inventory Time: Post treatment (15 weeks).Description: Twenty-four items evaluating six behaviors related to generalized anxiety, namely reassurance seeking, avoidance, control, procrastination, overplanning and checking. Items are rated on a five point Likert scale
Measure: Questionnaire of behavioral manifestations linked to anxiety Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Description: These items were added to describe the reality of the participants while considering the effects of the pandemic on their anxiety. Five questions are framed as "yes or no" with an open-ended description of their answer choice whereas four items are rated on a five-point Likert scale.
Measure: Nine items relating to COVID-19 Time: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports